Warner-Lambert Neurontin Surpasses Rezulin In Sales For The First Time
Executive Summary
Second quarter sales of Warner-Lambert's Neurontin (gabapentin) climbed 69% over the year-ago quarter, the company reported.
You may also be interested in...
W-L Expects Neurontin Sales To Reach $800 Mil. And Hold Through 2000
Warner-Lambert expects its anti-epileptic product Neurontin (gabapentin) to grow by more than 50% to $800 mil. this year and hold that level through its patent expiration year of 2000, the company said at a May 18 meeting with the New York Society of Securities Analysts.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials